CasNo.150322-43-3,Pharmaceutical Grade Prasugrel Raw Material Powder CAS 150322-43-3 Prasugrel,Prasugrel(150322-43-3) Suppliers

0	Negotiable

Min.Order :0
Purity: 99%

Keywords

Prasugrel Prasugrel powder 150322-43-3

Quick Details

Appearance:White powder
Application:Prasugrel is used in combination with low dose aspirin to prevent thrombosis in patients with acute coronary syndrome (ACS), including unstable angina pectoris, non-ST elevation myocardial infarct...
PackAge:Aluminum foil bag,fluorinated bottles,carboard drums or as your special request.
ProductionCapacity:
Storage:Store in cool & dry place. Keep away from strong light Shelf Life2 years when properly stored.
Transportation:1) Door to Door Service by DHL/FEDEX/EMS/TNT for package under 45kgs, about 3~7 days delivery. 2) Port to Port Service by Air for package more than 45kgs, about 3~7 days delivery. 3) Port to Port...

Superiority:

1) Provide costomers with "one-stop"packaging service,from research,development,production,export and so on.
2) We have our own R&D and production base,equipped with advanced production equipment and precision testing the Unitef States Pharmacopoeia(USP),the Britis Pharmacopoeia(EP) and other international advanced standards.All products are through the KOSGER,HALAL certification,the ISO quality management system certification and the HACCP certification.
3) More than 12 years of export experience.
4)Competitive price in China market.

Details:

Prasugrel (trade name Effient in the US and India, and Efient in the EU) is a pharmaceutical drug that acts as a platelet inhibitor and is used to prevent thrombosis (blood clotting). It was developed by Daiichi Sankyo Co. and produced by Ube and currently marketed in the United States in cooperation with Eli Lilly and Company.
Prasugrel was approved for use in Europe in February 2009, and in the US in July 2009, for the reduction of thrombotic cardiovascular events (including stent thrombosis) in people with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI).